Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COST-BENEFIT-ANALYSIS OF RISPERIDONE AND CLOZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ISRAEL
Autore:
GINSBERG G; SHANI S; LEV B;
Indirizzi:
DAN 8 IL-93509 JERUSALEM ISRAEL MINIST HLTH,DEPT MED TECHNOL ASSESSMENT JERUSALEM ISRAEL
Titolo Testata:
PharmacoEconomics
fascicolo: 2, volume: 13, anno: 1998,
pagine: 231 - 241
SICI:
1170-7690(1998)13:2<231:CORACI>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEUROLEPTIC-RESISTANT SCHIZOPHRENIA; LONG-TERM TREATMENT; DOUBLE-BLIND; REFRACTORY SCHIZOPHRENIA; EFFICACY; SAFETY; MULTICENTER; HALOPERIDOL; MANAGEMENT; INPATIENTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
61
Recensione:
Indirizzi per estratti:
Citazione:
G. Ginsberg et al., "COST-BENEFIT-ANALYSIS OF RISPERIDONE AND CLOZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ISRAEL", PharmacoEconomics, 13(2), 1998, pp. 231-241

Abstract

In this study, the benefits and costs of treating schizophrenia with either risperidone or clozapine were examined. The lifetime drug-treatment cost incurred by a patient with schizophrenia in Israel was $US7561 (1996 values) with an initial 6-month trial with risperidone, compared with $US6326 with clozapine and $US3360 with typical antipsychotics. Total lifetime costs of psychiatric health services (excluding medications) by individuals who were continuously receiving typical antipsychotics were $US181 555 per patient. Assuming a 6.3% decrease in hospital use with typical antipsychotics and an absolute 30% decrease withrisperidone or clozapine, the use of clozapine or risperidone reducedhospitalisation costs by $US7159 per patient, but increased community-care costs by $US1627 per patient, giving health-service benefit: cost ratios of 1.87 : 1 and 1.32 : 1, respectively. After adding indirectbenefits resulting from increased work productivity (minus indirect costs related to increases in transport costs because of visits for blood monitoring during clozapine therapy), the benefit : cost ratios increased to 2.04 : 1 and 1.48 : 1,respectively. Assuming that clozapine caused a 30% decrease in hospital use by patients with new-onset schizophrenia, risperidone would have to decrease hospital use by 43.2% (i.e. a 13.2% relative advantage) for its societal benefits to justify its increased costs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 01:17:43